Key terms

About VKTX

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest VKTX news

Apr 16 11:10pm ET LLY, VKTX, or NVO: Which Weight-Loss Drugmaker Could Gain the Best Returns? Apr 08 8:30am ET Wall Street Analysts Are Bullish on Top Healthcare Picks Apr 05 12:40pm ET Viking Therapeutics Stock (NASDAQ:VKTX): Analysts Stay Bullish on 2024’s Top Mid-Cap Mar 29 3:05am ET Buy Rating Affirmed for Viking Therapeutics Amid Promising Obesity Drug Trials and Strategic Market Positioning Mar 28 6:25am ET 3 Best Stocks to Buy Now, 3/28/2024, According to Top Analysts Mar 27 10:05pm ET Stifel Nicolaus Remains a Buy on Viking Therapeutics (VKTX) Mar 27 7:53am ET Viking Therapeutics price target raised to $138 from $116 at Oppenheimer Mar 26 3:25pm ET Buy Rating Affirmed for Viking Therapeutics on Strong Clinical Outcomes and Promising Obesity Program Mar 26 3:12pm ET Viking Therapeutics price target raised to $138 from $116 at Oppenheimer Mar 26 12:09pm ET Viking Therapeutics price target raised to $125 from $100 at BTIG Mar 26 10:55am ET Buy Rating Affirmed for Viking Therapeutics on Strong Phase 1 Results of Weight Loss Candidate VK2735 Mar 26 7:22am ET Viking Therapeutics Clarifies Regulatory Disclosure Status Mar 16 7:45am ET Buy Rating Affirmed for Viking Therapeutics: Promising NASH Treatments and Competitive Edge in Metabolic Disease Pipeline Mar 15 7:17am ET Approval of Madrigal’s Rezdiffra positive for Viking and MASH space, says Stifel Mar 15 7:14am ET Viking Therapeutics price target raised to $100 from $86 at BTIG Mar 11 12:47am ET Maintaining Buy on Viking Therapeutics: Overreaction to Competitor’s Data and Confidence in VK2735’s Market Potential Mar 08 7:15am ET Truist Financial Gives a Buy Rating to Viking Therapeutics (VKTX) Mar 08 6:30am ET Analysts Are Bullish on Top Healthcare Stocks: Lumos Pharma (LUMO), Arcturus Therapeutics (ARCT) Mar 07 3:34pm ET Novo results raising the bar for Viking’s oral VK2735, says Oppenheimer Mar 07 4:52am ET Viking Therapeutics initiated with a Buy at Jefferies Mar 07 4:21am ET Analysts Are Bullish on Top Healthcare Stocks: Viking Therapeutics (VKTX), Boston Scientific (BSX) Mar 03 5:25am ET BTIG Sticks to Its Buy Rating for Viking Therapeutics (VKTX) Mar 01 11:04am ET Biotech Alert: Searches spiking for these stocks today Mar 01 9:40am ET Unusually active option classes on open March 1st Mar 01 7:31am ET Viking Therapeutics price target raised to $120 from $38 at Truist Feb 29 10:57am ET Biotech Alert: Searches spiking for these stocks today Feb 29 10:57am ET Biotech Alert: Searches spiking for these stocks today Feb 29 10:39am ET Viking Therapeutics price target raised to $120 from $38 at Truist Feb 29 9:40am ET Unusually active option classes on open February 29th Feb 28 9:04pm ET Viking Therapeutics 6.47M share Secondary priced at $85.00 Feb 28 7:38am ET Viking Therapeutics price target raised to $116 from $46 at Oppenheimer

No recent press releases are available for VKTX

VKTX Financials

1-year income & revenue

Key terms

VKTX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

VKTX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms